DelveInsight’s “Hypophosphatasia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hypophosphatasia, historical and forecasted epidemiology as well as the Hypophosphatasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Hypophosphatasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypophosphatasia Market Forecast
Some of the key facts of the Hypophosphatasia Market Report:
The Hypophosphatasia market size was valued at ~USD 880 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
The pipeline for Hypophosphatasia is not very robust, consisting of REC-01, ALXN1850, and others which are expected to launch during the forecast period [2022-2032]
According to DelveInsight’s analysis, the diagnosed prevalent cases of Hypophosphatasia in the 7MM were estimated to be around 6,500 in 2023. This number is expected to rise by 2034 due to increased disease awareness among healthcare professionals and the general public worldwide.
In 2023, the US reported the highest diagnosed prevalence of hypophosphatasia among the 7MM, with approximately 6,000 cases. These numbers are expected to grow from 2024 to 2034, largely due to advancements in genetic testing that have enabled expanded newborn screening programs across the country.
Among the EU4 countries and the UK, Germany reported the highest number of diagnosed hypophosphatasia cases, with about 84 cases, followed by France with 69 cases, and the UK with 68 cases. These numbers are expected to increase by 2034, driven by a heightened focus on research and clinical trials for the disease.
In the UK, mild hypophosphatasia cases accounted for nearly 82%, moderate cases for 16%, and severe cases for 2% in 2023. The number of cases for each severity level is expected to rise by 2034.
Key Hypophosphatasia Companies: PuREC, AstraZeneca, Ultragenyx Pharmaceutical Inc., Alexion, and others
Key Hypophosphatasia Therapies: REC-01, ALXN1850, BPS804, asfotase alfa, and others
The Hypophosphatasia epidemiology based on severity-specific cases analyzed that mild Hypophosphatasia was most prevalent in the US, followed by moderate and severe Hypophosphatasia
The Hypophosphatasia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypophosphatasia pipeline products will significantly revolutionize the Hypophosphatasia market dynamics.
Hypophosphatasia Overview
Hypophosphatasia is a rare, inherited metabolic disorder caused by mutations in the ALPL gene, which affects the production of alkaline phosphatase (ALP) enzyme. This enzyme is essential for the proper mineralization of bones and teeth. In HPP, reduced ALP activity leads to defective bone development, resulting in conditions like rickets in children or osteomalacia in adults. Symptoms vary widely, ranging from severe skeletal abnormalities in infancy to milder issues in adulthood. The condition can also cause dental problems, muscle weakness, and respiratory complications. Hypophosphatasia is managed through supportive care and, in some cases, enzyme replacement therapy.
Get a Free sample for the Hypophosphatasia Market Report
https://www.delveinsight.com/sample-request/hypophosphatasia-market
Hypophosphatasia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hypophosphatasia Epidemiology Segmentation:
The Hypophosphatasia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Hypophosphatasia
Prevalent Cases of Hypophosphatasia by severity
Gender-specific Prevalence of Hypophosphatasia
Diagnosed Cases of Episodic and Chronic Hypophosphatasia
Download the report to understand which factors are driving Hypophosphatasia epidemiology trends @ Hypophosphatasia Epidemiology Forecast
Hypophosphatasia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypophosphatasia market or expected to get launched during the study period. The analysis covers Hypophosphatasia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hypophosphatasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hypophosphatasia Therapies and Key Companies
REC-01: PuREC
ALXN1850: AstraZeneca
BPS804: Ultragenyx Pharmaceutical Inc
Discover more about therapies set to grab major Hypophosphatasia market share @ Hypophosphatasia Treatment Market
Hypophosphatasia Market Strengths
Advancements in understanding the pathophysiology and genetics of Hypophosphatasia, thereby elucidating new targets for treatment
The approval of ERT by various regulatory authorities is a game changer, improving clinical manifestations, survival, and QoL
Hypophosphatasia Market Barriers
Developing specific biochemical biomarker-based assays with an increased understanding of differential diagnosis among physicians will lead to improvements in diagnosis, thus opening the windows of opportunity for new treatment options
There is a need for pharmacotherapeutic interventions for milder adult-onset of disease, which has little mortality and a high disease burden
Scope of the Hypophosphatasia Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Hypophosphatasia Therapeutic Assessment: Hypophosphatasia current marketed and Hypophosphatasia emerging therapies
Hypophosphatasia Market Dynamics: Hypophosphatasia market drivers and Hypophosphatasia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Hypophosphatasia Unmet Needs, KOL’s views, Analyst’s views, Hypophosphatasia Market Access and Reimbursement
To know more about Hypophosphatasia companies working in the treatment market, visit @ Hypophosphatasia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Hypophosphatasia Market Report Introduction
2. Executive Summary for Hypophosphatasia
3. SWOT analysis of Hypophosphatasia
4. Hypophosphatasia Patient Share (%) Overview at a Glance
5. Hypophosphatasia Market Overview at a Glance
6. Hypophosphatasia Disease Background and Overview
7. Hypophosphatasia Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypophosphatasia
9. Hypophosphatasia Current Treatment and Medical Practices
10. Hypophosphatasia Unmet Needs
11. Hypophosphatasia Emerging Therapies
12. Hypophosphatasia Market Outlook
13. Country-Wise Hypophosphatasia Market Analysis (2020–2034)
14. Hypophosphatasia Market Access and Reimbursement of Therapies
15. Hypophosphatasia Market Drivers
16. Hypophosphatasia Market Barriers
17. Hypophosphatasia Appendix
18. Hypophosphatasia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
